Neuroblastoma (NBL) is the most common extracranial childhood malignant tumor and represents a major cause of cancer-related deaths in infants. NMYC amplification or overexpression is associated with the malignant behavior of NBL tumors. In the present study, we revealed an association between long non-coding RNA (lncRNA) myocardial infarction associated transcript (MIAT) and NMYC amplification in NBL cell lines and MIAT expression in NBL tissue samples. MIAT silencing induces cell death only in cells with NMYC amplification, but in NBL cells without NMYC amplification it decreases only the proliferation. MIAT downregulation markedly reduces the NMYC expression in NMYC-amplified NBL cell lines and c-Myc expression in NMYC non-amplified NBL cell lines, but the ectopic overexpression or downregulation of NMYC did not affect the expression of MIAT. Moreover, MIAT downregulation results in decreased ornithine decarboxylase 1 (ODC1), a known transcriptional target of MYC oncogenes, and decreases the glycolytic metabolism and respiratory function. These results indicate that MIAT is an upstream regulator of NMYC and that MIAT/NMYC axis disruption induces cell death in NMYC-amplified NBL cell lines. These findings reveal a novel mechanism for the regulation of NMYC in NBL, suggesting that MIAT might be a potential therapeutic target, especially for those with NMYC amplification.

Department of Pathology and Molecular Medicine 2nd Faculty of Medicine Charles University and Motol University Hospital 5 Uvalu 84 150 06 Prague Czech Republic

Department of Pediatric Hematology and Oncology 2nd Faculty of Medicine Charles University and Motol University Hospital 5 Uvalu 84 150 06 Prague Czech Republic

See more in PubMed

Luksch R., Castellani M.R., Collini P., De Bernardi B., Conte M., Gambini C., Gandola L., Garaventa A., Biasoni D., Podda M., et al. Neuroblastoma (Peripheral neuroblastic tumours) Crit. Rev. Oncol. Hematol. 2016;107:163–181. doi: 10.1016/j.critrevonc.2016.10.001. PubMed DOI

Huang M., Weiss W.A. Neuroblastoma and MYCN. Cold Spring Harb. Perspect. Med. 2013;3:a014415. doi: 10.1101/cshperspect.a014415. PubMed DOI PMC

Brodeur G.M. Neuroblastoma: Biological insights into a clinical enigma. Nat. Rev. Cancer. 2003;3:203–216. doi: 10.1038/nrc1014. PubMed DOI

Maris J.M. Recent advances in neuroblastoma. N. Engl. J. Med. 2010;362:2202–2211. doi: 10.1056/NEJMra0804577. PubMed DOI PMC

Li J., Liu C. Coding or noncoding, the converging concepts of RNAs. Front. Genet. 2019;10 doi: 10.3389/fgene.2019.00496. PubMed DOI PMC

Peinado P., Herrera A., Baliñas C., Martín-Padrón J., Boyero L., Cuadros M., Coira I.F., Rodriguez M.I., Reyes-Zurita F.J., Rufino-Palomares E.E., et al. Cancer and Noncoding RNAs. Elsevier; Amsterdam, The Netherlands: 2018. Long Noncoding RNAs as Cancer Biomarkers; pp. 95–114.

Sahu D., Ho S.Y., Juan H.F., Huang H.C. High-risk, expression-based prognostic long noncoding RNA signature in neuroblastoma. JNCI Cancer Spectr. 2018;2:pky015. doi: 10.1093/jncics/pky015. PubMed DOI PMC

Swier L.J.Y.M., Dzikiewicz-Krawczyk A., Winkle M., van den Berg A., Kluiver J. Intricate crosstalk between MYC and non-coding RNAs regulates hallmarks of cancer. Mol. Oncol. 2019;13:26–45. doi: 10.1002/1878-0261.12409. PubMed DOI PMC

Rombaut D., Chiu H.S., Decaesteker B., Everaert C., Yigit N., Peltier A., Janoueix I., Bartenhagen C., Fischer M., Roberts S., et al. Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes. Sci. Rep. 2019;9:1–13. doi: 10.1038/s41598-019-42107-y. PubMed DOI PMC

Song F., Yang Y., Liu J. Long non-coding RNA MIAT promotes the proliferation and invasion of laryngeal squamous cell carcinoma cells by sponging microRNA-613. Exp. Ther. Med. 2021;21:1. doi: 10.3892/etm.2021.9663. PubMed DOI PMC

Xu H., Zhou J., Tang J., Min X., Yi T., Zhao J., Ren Y. Identification of serum exosomal lncRNA MIAT as a novel diagnostic and prognostic biomarker for gastric cancer. J. Clin. Lab. Anal. 2020;34:e23323. doi: 10.1002/jcla.23323. PubMed DOI PMC

Qu Y., Xiao H., Xiao W., Xiong Z., Hu W., Gao Y., Ru Z., Wang C., Bao L., Wang K., et al. Upregulation of MIAT Regulates LOXL2 Expression by Competitively Binding miR-29c in Clear Cell Renal Cell Carcinoma. Cell. Physiol. Biochem. 2018;48:1075–1087. doi: 10.1159/000491974. PubMed DOI

Jin H., Jin X., Chai W., Yin Z., Li Y., Dong F., Wang W. Long non-coding RNA MIAT competitively binds miR-150-5p to regulate ZEB1 expression in osteosarcoma. Oncol. Lett. 2019;17:1229–1236. doi: 10.3892/ol.2018.9671. PubMed DOI PMC

Zhao H.L., Xu S.Q., Li Q., Zhao Y.B., Li X., Yang M.P. Long noncoding RNA MIAT promotes the growth and metastasis of non-small cell lung cancer by upregulating TDP43. Eur. Rev. Med. Pharmacol. Sci. 2019;23:3383–3389. PubMed

Li T.F., Liu J., Fu S.J. The interaction of long non-coding RNA MIAT and miR-133 play a role in the proliferation and metastasis of pancreatic carcinoma. Biomed. Pharmacother. 2018;104:145–150. doi: 10.1016/j.biopha.2018.05.043. PubMed DOI

Fu Y., Li C., Luo Y., Li L., Liu J., Gui R. Silencing of long non-coding RNA MIAT sensitizes lung cancer cells to gefitinib by epigenetically regulating miR-34a. Front. Pharmacol. 2018;9 doi: 10.3389/fphar.2018.00082. PubMed DOI PMC

Huang X., Gao Y., Qin J., Lu S. lncRNA MIAT promotes proliferation and invasion of HCC cells via sponging miR-214. Am. J. Physiol. Gastrointest. Liver Physiol. 2018;314:G559–G565. doi: 10.1152/ajpgi.00242.2017. PubMed DOI

Xiang Y., Huang Y., Sun H., Pan Y., Wu M., Zhang J. Deregulation of miR-520d-3p promotes hepatocellular carcinoma development via lncRNA MIAT regulation and EPHA2 signaling activation. Biomed. Pharmacother. 2019;109:1630–1639. doi: 10.1016/j.biopha.2018.11.014. PubMed DOI

Li D., Hu X., Yu S., Deng S., Yan M., Sun F., Song J., Tang L. Silence of lncRNA MIAT-mediated inhibition of DLG3 promoter methylation suppresses breast cancer progression via the Hippo signaling pathway. Cell. Signal. 2020;73:109697. doi: 10.1016/j.cellsig.2020.109697. PubMed DOI

Li Y., Wang K., Wei Y., Yao Q., Zhang Q., Qu H., Zhu G. lncRNA-MIAT regulates cell biological behaviors in gastric cancer through a mechanism involving the miR-29a-3p/HDAC4 axis. Oncol. Rep. 2017;38:3465–3472. doi: 10.3892/or.2017.6020. PubMed DOI

Aprea J., Prenninger S., Dori M., Ghosh T., Monasor L.S., Wessendorf E., Zocher S., Massalini S., Alexopoulou D., Lesche M., et al. Transcriptome sequencing during mouse brain development identifies long non-coding RNAs functionally involved in neurogenic commitment. EMBO J. 2013;32:3145–3160. doi: 10.1038/emboj.2013.245. PubMed DOI PMC

Bountali A., Tonge D.P., Mourtada-Maarabouni M. RNA sequencing reveals a key role for the long non-coding RNA MIAT in regulating neuroblastoma and glioblastoma cell fate. Int. J. Biol. Macromol. 2019;130:878–891. doi: 10.1016/j.ijbiomac.2019.03.005. PubMed DOI

Prochazka P., Hrabeta J., Vicha A., Cipro S., Stejskalova E., Musil Z., Vodicka P., Eckschlager T. Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers. Oncol. Rep. 2013;29:2415–2421. doi: 10.3892/or.2013.2383. PubMed DOI

Aygun N., Altungoz O. MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines. Mol. Med. Rep. 2019;19:345–361. doi: 10.3892/mmr.2018.9686. PubMed DOI PMC

Wang H., Mannava S., Grachtchouk V., Zhuang D., Soengas M.S., Gudkov A.V., Prochownik E.V., Nikiforov M.A. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene. 2008;27:1905–1915. doi: 10.1038/sj.onc.1210823. PubMed DOI PMC

Li X., Zhao H., Liu J., Tong J. Long Non-coding RNA MIAT Knockdown Prevents the Formation of Intracranial Aneurysm by Downregulating ENC1 via MYC. Front. Physiol. 2021;11 doi: 10.3389/fphys.2020.572605. PubMed DOI PMC

Raul F. Revival of 2-(difluoromethyl)ornithine (DFMO), an inhibitor of polyamine biosynthesis, as a cancer chemopreventive agent. Biochem. Soc. Trans. 2007;35:353–355. doi: 10.1042/BST0350353. PubMed DOI

Hogarty M.D., Norris M.D., Davis K., Liu X., Evageliou N.F., Hayes C.S., Pawel B., Guo R., Zhao H., Sekyere E., et al. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res. 2008;68:9735–9745. doi: 10.1158/0008-5472.CAN-07-6866. PubMed DOI PMC

Bell E., Chen L., Liu T., Marshall G.M., Lunec J., Tweddle D.A. MYCN oncoprotein targets and their therapeutic potential. Cancer Lett. 2010;293:144–157. doi: 10.1016/j.canlet.2010.01.015. PubMed DOI

Yildirim O., Izgu E.C., Damle M., Chalei V., Ji F., Sadreyev R.I., Szostak J.W., Kingston R.E. S-phase Enriched Non-coding RNAs Regulate Gene Expression and Cell Cycle Progression. Cell Rep. 2020;31:107629. doi: 10.1016/j.celrep.2020.107629. PubMed DOI PMC

Ren P., Yue M., Xiao D., Xiu R., Gan L., Liu H., Qing G. ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation. J. Pathol. 2015;235:90–100. doi: 10.1002/path.4429. PubMed DOI

Zirath H., Frenzel A., Oliynyk G., Segerström L., Westermark U.K., Larsson K., Persson M.M., Hultenby K., Lehtiö J., Einvik C., et al. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc. Natl. Acad. Sci. USA. 2013;110:10258–10263. doi: 10.1073/pnas.1222404110. PubMed DOI PMC

Qing G., Skuli N., Mayes P.A., Pawel B., Martinez D., Maris J.M., Simon M.C. Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1α. Cancer Res. 2010;70:10351–10361. doi: 10.1158/0008-5472.CAN-10-0740. PubMed DOI PMC

Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. PubMed DOI

Pfaffl M.W. Relative expression software tool (REST(C)) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30:e36. doi: 10.1093/nar/30.9.e36. PubMed DOI PMC

KDM5B expression in cisplatin resistant neuroblastoma cell lines